| Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer J Cortes, HS Rugo, DW Cescon, SA Im, MM Yusof, C Gallardo, O Lipatov, ... New England Journal of Medicine 387 (3), 217-226, 2022 | 418 | 2022 |
| Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial EP Winer, O Lipatov, SA Im, A Goncalves, E Muñoz-Couselo, KS Lee, ... The Lancet Oncology 22 (4), 499-511, 2021 | 341 | 2021 |
| KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC) J Cortés, O Lipatov, SA Im, A Gonçalves, KS Lee, P Schmid, K Tamura, ... Annals of Oncology 30, v859-v860, 2019 | 163* | 2019 |
| LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab+ chemotherapy vs placebo+ chemotherapy for metastatic TNBC J Cortés, DW Cescon, HS Rugo, SA Im, MM Yusof, C Gallardo, O Lipatov, ... Annals of Oncology 32, S1289-S1290, 2021 | 33 | 2021 |
| Outcome-weighted learning for personalized medicine with multiple treatment options X Zhou, Y Wang, D Zeng 2018 IEEE 5th international conference on data science and advanced …, 2018 | 19 | 2018 |
| Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab+ chemotherapy vs placebo+ chemotherapy for previously untreated locally recurrent … J Cortes, DW Cescon, HS Rugo San Antonio Breast Cancer Symposium 2021, GS1-02, 2021 | 17 | 2021 |
| KEYNOTE-C93/GOG-3064/ENGOT-en15: A phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced … BM Slomovitz, D Cibula, T Simsek, MR Mirza, B Maćkowiak-Matejczk, ... Journal of Clinical Oncology 40 (16_suppl), TPS5623-TPS5623, 2022 | 16 | 2022 |
| Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil M Ascha, X Zhou, Y Rao, OA Minai, AR Tonelli Cardiovascular therapeutics 35 (5), e12281, 2017 | 12 | 2017 |
| Population distributions of thymic function in adults: variation by sociodemographic characteristics and health status L Feinstein, S Ferrando-Martínez, M Leal, X Zhou, GD Sempowski, ... Biodemography and social biology 62 (2), 208-221, 2016 | 10 | 2016 |
| KEYNOTE-355: Final results from a randomized, double-blind, phase 3 study of first-line pembrolizumab+ chemotherapy vs placebo+ chemotherapy for metastatic TNBC H Rugo, J Cortes, DW Cescon, SA Im, MM Usof, C Gallardo, O Lipatov, ... ESMO Congress, 2021 | 8* | 2021 |
| Do single or sequential measurements of leptin and adiponectin in plasma have prognostic value in pulmonary arterial hypertension? AR Tonelli, WH Fares, W Dakkak, Y Rao, X Zhou, RA Dweik Pulmonary Circulation 7 (3), 727-729, 2017 | 7 | 2017 |
| Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab+ chemotherapy vs placebo+ chemotherapy for previously untreated locally … J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im, MM Yusof, C Gallardo, ... Cancer Research 82 (4_Supplement), GS1-02-GS1-02, 2022 | 5 | 2022 |
| 164O Health-related quality of life (HRQoL) with pembrolizumab (pembro)+ chemotherapy (chemo) vs placebo (pbo)+ chemo as 1L treatment for advanced triple-negative breast cancer … DW Cescon, P Schmid, HS Rugo, SA Im, MM Yusof, CE Gallardo, ... Annals of Oncology 33, S197-S198, 2022 | 3 | 2022 |
| 141P impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple negative breast cancer P Schmid, A Haiderali, J Mejia, Z Guo, X Zhou, A Martin-Nguyen, J Cortés, ... Annals of Oncology 31, S65-S66, 2020 | 3 | 2020 |
| Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised … P Schmid, O Lipatov, SA Im, A Goncalves, E Muñoz-Couselo, KS Lee, ... European Journal of Cancer 195, 113393, 2023 | 1 | 2023 |
| TP016/# 1442 Keynote-C93/GOG-3064/ENGOT-EN15: phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair … B Slomovitz, D Cibula, M Gultekin, M Mirza, B Maćkowiak-Matejczyk, ... International Journal of Gynecologic Cancer 32 (Suppl 3), 2022 | 1 | 2022 |
| Pembrolizumab in Triple-Negative Breast Cancer. Reply. J Cortes, X Zhou, P Schmid The New England journal of medicine 387 (15), 1436-1436, 2022 | 1 | 2022 |
| Bayesian decision making in confirmatory early-stage breast cancer trial E Gu, X Zhou, J Zhao Contemporary Clinical Trials 102, 106280, 2021 | 1 | 2021 |
| Multicategory Classification Via Forward–Backward Support Vector Machine X Zhou, Y Wang, D Zeng Communications in Mathematics and Statistics, 2019 | 1 | 2019 |
| BELLWAVE-010: A phase 3 study of nemtabrutinib plus venetoclax versus venetoclax plus rituximab (VR) in previously treated patients (pts) with relapsed/refractory (R/R) chronic … M Ozcan, D Lavie, A Chaudhry, X Zhou, I Paydar, MZH Farooqui, P Ghia Journal of Clinical Oncology 42 (16_suppl), TPS7089-TPS7089, 2024 | | 2024 |
